Relatively simple improvements could increase patient satisfaction and potentially improve the important process of imparting patient information during enrollment of cancer patients into clinical trials.
Relatively simple improvements could increase patient satisfaction and potentially improve the important process of imparting patient information during enrollment of cancer patients into clinical trials, according to a study published in BMC Health Services Research.
Since enrollment into clinical trials is vital to the process of developing, evaluating, and implementing new cancer treatments, efforts must be made to improve the consent process, particularly the written forms, concluded study authors, Pia Dellson and colleagues at the Institute of Clinical Sciences at Lund University, Sweden. They note that written consent materials should be complete, but at the same time not so complex that it may be questioned if fully informed consent is even possible to provide.
Their study explored patient representatives’ views and perceptions of written consent information used in 4 colorectal cancer clinical trials through the use of focus groups. Fourteen patients enrolled in randomized and nonrandomized phase I, II, and III trials that evaluated chemotherapy/targeted therapy were involved in the focus groups. Each had been diagnosed with colorectal cancer 1 to 8 years prior to the study.
The authors explain that oral clinical trial information is provided to patients by physicians and research nurses, but that written informed consent forms are typically developed by study sponsors who may represent academic researchers or commercial companies. The written information is typically extensive, providing a full and comprehensive picture of potential risks and benefits.
Though patients are generally satisfied with the consent process, studies have shown that their understanding of study aims, treatment risks and benefits, and randomization and research aspects are suboptimal.
Two major themes emerged from the focus groups, which researchers classified as emotional responses (including individual preferences and perceptions of effects) and cognitive responses (including comprehensibility and layout). Based on their findings, patient representatives suggested improvements in written consent materials. The suggested improvements were simple, and entailed the use of simplified and plain language, and structured text and illustrations to create more attractive informed consent forms.
The study authors suggest that future written consent information be developed with the aid of professional writers, illustrators, and patient representatives.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More